查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566970

臨床免疫分析儀市場：按類型、應用和最終用戶分類：2024-2033 年全球機會分析和產業預測

Clinical Immunoanalyzer Market By Type , By Application By End user : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 216 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023年臨床免疫分析儀市值為47億美元，預計2024年至2033年複合年成長率為5.5%，到2033年達到80億美元。

臨床免疫分析儀是醫學實驗室使用的診斷儀器，用於對患者樣本中的各種免疫標記物（例如抗體、抗原和其他免疫系統成分）進行定量和定性分析。臨床免疫分析儀透過提供準確、快速的結果，在診斷疾病、監測免疫反應和確定臨床治療策略方面發揮重要作用。這些分析儀可以快速提供測試結果，對於及時診斷和治療決策至關重要。

全球臨床免疫分析儀市場的成長是由癌症、自體免疫疾病和感染疾病等慢性病盛行率的驚人上升以及對早期和準確診斷的日益重視所推動的。根據研究，全球約20%的人口患有糖尿病、心血管疾病等慢性疾病，需要定期監測和診斷。因此，對能夠有效檢測相關生物標記的臨床免疫分析儀的需求不斷成長。此外，老年人口的快速成長是全球市場的主要驅動力。這是因為老年人更容易患各種疾病，這增加了對先進診斷解決方案的需求。根據世界衛生組織（WHO）的數據，2019年60歲以上的人口有10億人。預計到 2030 年，這一數字將增至 14 億，到 2050 年將增至 21 億。隨著老年人口的增加，慢性病的盛行率預計將顯著增加。此外，人們對健康和預防性醫療保健的認知不斷提高，正在推動先進診斷工具的使用，以實現更好的健康管理，從而促進市場成長。製造商專注於免疫分析儀自動化，以簡化實驗室工作流程、減少人為錯誤並提高通量。我們還將人工智慧和機器學習整合到我們的免疫分析儀中，以增強資料解釋、自動化流程並提高診斷準確性。這些趨勢極大地促進了先進診斷設備採用率的提高。然而，先進免疫分析儀的初始投資和維護成本較高，以及需要定期維護、校準和技術支持，限制了市場成長。此外，許多國家沒有足夠的醫療設施來滿足其公民的需求，而有限的醫療服務是市場的主要阻礙因素。另一方面，檢測技術的不斷改進，提高了靈敏度和特異性，使生物標記的檢測更加準確和可靠，可能有利於預測期內全球市場的擴張。此外，新興市場醫療基礎設施的開拓正在推動這些地區臨床免疫分析儀的採用並擴大市場規模。

全球臨床免疫分析儀產業按類型、應用、最終用戶和地區細分。按類型分類，市場分為 ELISA、CLIA、RIA 等。依用途分為臨床化學、內分泌、腫瘤、感染疾病診斷、循環系統等。依最終用戶分類，可分為醫院/診所、診斷實驗室、研究機構等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類，ELISA 細分市場預計將在 2024 年至 2033 年期間佔據市場主導地位。

從應用來看，感染疾病診斷預計將成為預測期內的主要部分。

醫院和診所預計將成為未來幾年臨床免疫分析儀的主要最終用戶。

按地區分類，臨床免疫分析儀市場在不久的將來可能會在北美出現顯著成長。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣新增其他公司簡介
  • 平均銷售價格分析/價格分佈分析
  • 擴大公司簡介列表
  • 贖回場景

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章臨床免疫分析儀市場：依類型

  • 市場概況
  • ELISA
  • CLIA
  • RIA
  • 其他

第5章臨床免疫分析儀市場：依應用分類

  • 市場概況
  • 臨床化學
  • 內分泌學
  • 腫瘤學
  • 感染疾病診斷
  • 循環系統
  • 其他

第6章 臨床免疫分析儀市場：依最終使用者分類

  • 市場概況
  • 醫院和診所
  • 診斷實驗室
  • 研究所
  • 其他

第7章臨床免疫分析儀市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國臨床免疫分析儀市場
    • 加拿大臨床免疫分析儀市場
    • 墨西哥臨床免疫分析儀市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 法國臨床免疫分析儀市場
    • 德國臨床免疫分析儀市場
    • 義大利臨床免疫分析儀市場
    • 西班牙臨床免疫分析儀市場
    • 英國臨床免疫分析儀市場
    • 其他歐洲臨床免疫分析儀市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 中國臨床免疫分析儀市場
    • 日本臨床免疫分析儀市場
    • 印度臨床免疫分析儀市場
    • 韓國臨床免疫分析儀市場
    • 澳洲臨床免疫分析儀市場
    • 其他亞太臨床免疫分析儀市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西臨床免疫分析儀市場
    • 南非臨床免疫分析儀市場
    • 沙烏地阿拉伯臨床免疫分析儀市場
    • 其他拉丁美洲/中東/非洲臨床免疫分析儀市場

第8章 競爭格局

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第9章 公司簡介

  • Roche Diagnostics Corporation
  • Abbott
  • Siemens AG.
  • Beckman Coulter
  • Ortho-Clinical Diagnostics
  • Bio-Rad
  • BioMerieux
  • DiaSorin SpA
  • Werfen Life
  • Thermo Fisher Scientific
簡介目錄
Product Code: A324391

The clinical immunoanalyzer market was valued at $4.7 billion in 2023, and is projected to reach $8.0 billion by 2033, growing at a CAGR of 5.5% from 2024 to 2033.

Clinical immunoanalyzer is a diagnostic instrument used in medical laboratories to perform quantitative and qualitative analyses of various immunological markers such as antibodies, antigens, and other immune system components in patient samples. By providing accurate and rapid results, clinical immunoanalyzers play a critical role in diagnosing diseases, monitoring immune responses, and guiding treatment decisions in clinical settings. These analyzers deliver quick turnaround times for test results, which is crucial for timely diagnosis and treatment decisions.

The growth of the global clinical immunoanalyzer market is driven by alarming rise in prevalence of chronic conditions such as cancer, autoimmune diseases, and infectious diseases and increase in emphasis on early and precise diagnosis. Studies have shown that approximately 20% of the global population suffers from chronic diseases such as diabetes and cardiovascular disorders, which require regular monitoring and diagnostics. This drives the demand for clinical immunoanalyzers capable of efficiently detecting relevant biomarkers. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that aged individuals are highly susceptible to various diseases, which fosters the need for advanced diagnostic solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. With increasing aged population, the incidence of chronic conditions is expected to rise significantly. Moreover, increase in awareness about health and preventive care promotes the use of advanced diagnostic tools for better health management, which augments the market growth. Manufacturers are focusing on automation of immunoanalyzers to streamline laboratory workflows, reduce human error, and increase throughput as well as integration of AI and ML into immunoanalyzers to enhance data interpretation, automate processes, and improve diagnostic accuracy. These trends are notably contributing to higher adoption rates of advanced diagnostic equipment. However, high initial investment and maintenance costs of advanced immunoanalyzers and need for regular maintenance, calibration, and technical support restrain the market growth. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, ongoing improvements in assay technologies are leading to higher sensitivity and specificity to enable more accurate and reliable detection of biomarker are expected to offer lucrative opportunities for expansion of the global market during the forecast period. Furthermore, development of healthcare infrastructure in emerging markets is driving the adoption of clinical immunoanalyzers in these regions, expanding market reach.

The global clinical immunoanalyzer industry is segmented into type, application, end user, and region. On the basis of type, the market is categorized into ELISA, CLIA, RIA, and others. Depending on application, it is categorized into clinical chemistry, endocrinology, oncology, infectious disease diagnostics, cardiology, and others. By end user, it is fragmented into hospitals & clinics, diagnostic laboratories, research institutes, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the ELISA segment is expected to dominate the market from 2024 to 2033.

On the basis of application, infectious disease diagnostics is anticipated to emerge as the leading segment during the forecast period.

The hospitals & clinics segment is projected to serve as the major end user of clinical immunoanalyzers in the coming years.

Region wise, the clinical immunoanalyzer market is likely to experience significant growth across North America in the near future.

Competition Analysis

Competitive analysis and profiles of the major players in the global clinical immunoanalyzer market include Roche Diagnostics Corporation, Abbott, Siemens AG., Beckman Coulter, Ortho-Clinical Diagnostics, Bio-Rad, bioMerieux, DiaSorin S.p.A., Werfen Life, and Thermo Fisher Scientific. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and strengthen their foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Average Selling Price Analysis / Price Point Analysis
  • Expanded list for Company Profiles
  • Reimbursement Scenario

Key Market Segments

By Type

  • ELISA
  • CLIA
  • RIA
  • Others

By Application

  • Clinical Chemistry
  • Endocrinology
  • Oncology
  • Infectious Disease Diagnostics
  • Cardiology
  • Others

By End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Roche Diagnostics Corporation
    • Abbott
    • Siemens AG.
    • Beckman Coulter
    • Ortho-Clinical Diagnostics
    • Bio-Rad
    • bioMerieux
    • DiaSorin S.p.A.
    • Werfen Life
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CLINICAL IMMUNOANALYZER MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. ELISA
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. CLIA
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. RIA
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Others
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: CLINICAL IMMUNOANALYZER MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Clinical Chemistry
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Endocrinology
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Oncology
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Infectious Disease Diagnostics
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Cardiology
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Others
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country

CHAPTER 6: CLINICAL IMMUNOANALYZER MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Research Institutes
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country
  • 6.5. Others
    • 6.5.1. Key Market Trends, Growth Factors and Opportunities
    • 6.5.2. Market Size and Forecast, By Region
    • 6.5.3. Market Share Analysis, By Country

CHAPTER 7: CLINICAL IMMUNOANALYZER MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Clinical Immunoanalyzer Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Clinical Immunoanalyzer Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Clinical Immunoanalyzer Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Clinical Immunoanalyzer Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. Germany Clinical Immunoanalyzer Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. Italy Clinical Immunoanalyzer Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Spain Clinical Immunoanalyzer Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. UK Clinical Immunoanalyzer Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Clinical Immunoanalyzer Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Clinical Immunoanalyzer Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. Japan Clinical Immunoanalyzer Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Clinical Immunoanalyzer Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. South Korea Clinical Immunoanalyzer Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. Australia Clinical Immunoanalyzer Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Clinical Immunoanalyzer Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Clinical Immunoanalyzer Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. South Africa Clinical Immunoanalyzer Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. Saudi Arabia Clinical Immunoanalyzer Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Clinical Immunoanalyzer Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Roche Diagnostics Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Abbott
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Siemens AG.
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Beckman Coulter
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Ortho-Clinical Diagnostics
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Bio-Rad
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. BioMerieux
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. DiaSorin S.p.A.
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Werfen Life
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Thermo Fisher Scientific
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments